NEW LIMITATION CHANGE

TO
Approved for public release, distribution unlimited

FROM
Distribution authorized to U.S. Gov't. agencies and their contractors;
Administrative/Operational use; 15 Aug 1961. Other requests shall be referred to
Army Medical Research Lab, Fort Knox KY.

AUTHORITY
USAMRL LTR, 26 FEB 70 [71-14]
"NOTICE: When Government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related Government procurement operation, the U.S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated furnished, or in any way supplied the said drawings, specifications or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.
REDUCTION OF RADIATION LETHALITY IN DOGS BY CHEMICAL MIXTURE

Capt Richard I. H. Wang, MC
Lt David E. Davidson, Jr., VC

Study of Protective Agents
Task 04
Biological and Medical Aspects of Ionizing Radiation
USAMR Project No. UX64-14-001

UNITED STATES ARMY
MEDICAL RESEARCH AND DEVELOPMENT COMMAND 15 August 1961
Report Submitted 5 May 1961

Authors
Capt Richard I. H. Wanr, MC* (M.D., Ph.D) Chief, Chronic Irradiation Branch Radiobiology Division
Lt David E. Davidson, Jr., VC (V.M.D.) Chronic Irradiation Branch Radiobiology Division

Technical Assistants
Sp4 Robert M. Dunton Chronic Irradiation Branch Radiobiology Division
(B.S.)
Sp4 William L. Orton Chronic Irradiation Branch Radiobiology Division
(B.A.)
Pfc Melvin S. Klugman Chronic Irradiation Branch Radiobiology Division

*Presently at Roswell Park Memorial Institute, Buffalo, New York

Qualified requestors may obtain copies of this report from ASTIA.

Foreign announcement and dissemination of this report by ASTIA is limited.
ABSTRACT

REDUCTION OF RADIATION LETHALITY IN DOGS
BY CHEMICAL MIXTURE

OBJECT

To determine whether the pre-irradiation administration of mixtures of chemical agents to dogs, with or without post-irradiation supportive therapy, can provide effective protection from supra-lethal total-body doses of ionizing radiation.

RESULTS AND CONCLUSIONS

A total of 68 small dogs were individually exposed to supra-lethal doses of 600 r (1.8 x LD$_{100}$) of acute whole-body radiation from a cobalt 60 source. The administration of 4 to 5 mg/kg of para-aminopropiophenone (PAPP) intravenously 30 minutes before, and 225 mg (total dose) of S-β-aminoethylisothiuronium (AET) plus 32.5 mg (total dose) of serotonin intraperitoneally 10 to 15 minutes before irradiation provided 58 per cent survival, whereas the administration of PAPP alone protected only 13 per cent. By supplementing this pre-irradiation chemical treatment with post-irradiation supportive therapy consisting of antibiotics, vitamins, parenteral fluids, and whole-blood transfusions, the survival of the PAPP treated dogs was increased to 63 per cent, while the survival of the dogs receiving the chemical mixture was increased to 82 per cent. Post-irradiation supportive therapy increased the mean survival time of control irradiated dogs by 4 days, but effected survival beyond 30 days in only one case. Pre-treatment with chemical agents seemed to influence favorably the post-irradiation fall in leucocytes, but did not noticeably effect the hematocrit or hemoglobin levels. No deaths occurred as a direct result of the toxicity of the chemical agents; furthermore, the intravenous administration of methylene blue immediately following irradiation rapidly reversed the toxic effects.

RECOMMENDATIONS

It is recommended that this and other mixtures of chemical radio-protective agents be investigated further in dogs with a view toward possible human application.
REDUCTION OF RADIATION LETHALITY IN DOGS
BY CHEMICAL MIXTURE

I. INTRODUCTION

Effective protection from radiation induced lethality in rodents by the pre-irradiation administration of various chemical agents has been demonstrated by numerous investigators. In this laboratory an improved degree of protection in mice against supra-lethal doses of whole-body X-irradiation has been achieved by the pre-irradiation administration of a mixture of radio-protective chemicals containing S, \( \beta \)-aminoethylisothiuronium (AET), \( \beta \)-mercaptoethylamine (MEA) and serotonin (1). By supplementing the above chemical treatment with the use of lead-grid partial-body shielding during irradiation or the transplantation of isologous bone marrow following irradiation, further increases in the survival of mice at supra-lethal doses of X-radiation were obtained (2, 3).

Attempts to protect dogs from radiation induced lethality using single chemical agents have been rather disappointing (4); however, using a mixture of AET and para-aminopropiophenone (PAPP), Blouin and Overman, in a preliminary paper, reported 83 to 100 per cent survival in dogs following exposure to 500 r (1.25 \( \times \) LD\(_{100}\)) of X-radiation (5). Similarly, Jacobus used high doses of MEA and cysteine combined to protect dogs against 700 or 775 r of X-rays (6).

It has been reported that streptomycin and bone marrow therapy in mice following supra-lethal X-irradiation enhances the protection afforded by pre-treatment with AET (7). Furthermore, the beneficial effects of post-irradiation therapy with antibiotics, vitamins, and whole blood transfusions have been demonstrated in sublethally irradiated dogs (8-12). The effectiveness of such post-irradiation therapy in chemically protected, supra-lethally irradiated dogs has not previously been reported in the literature.

The present study was undertaken to determine, firstly, the degree of radiation protection which could be obtained in dogs by the prior administration of a mixture of chemical agents; and, secondly, the effect of post-irradiation supportive therapy on the percentage of survival of chemically pre-treated, irradiated dogs.

II. EXPERIMENTAL

A total of 68 healthy, mature, mongrel dogs of both sexes, weighing 6.5 to 11.0 kg were used in this study. All dogs were individually
exposed to supra-lethal doses of 600 r of acute whole-body radiation from a cobalt 60 source. The dogs to be irradiated were assigned randomly to the following groups:

Group I. Control (No Pre-treatment)
   a. With post-irradiation supportive therapy
   b. Without post-irradiation supportive therapy

Group II. Pre-treatment with PAPP
   a. With post-irradiation supportive therapy
   b. Without post-irradiation supportive therapy

Group III. Pre-treatment with PAPP, AET and Serotonin
   a. With post-irradiation supportive therapy
   b. Without post-irradiation supportive therapy

Prior to their use in this study, the dogs were quarantined for two weeks, given anthelmintics and vaccinated against canine distemper, hepatitis, and rabies. They were then moved to individual metal cages in an air-conditioned building and observed for an additional week. One pound of a commercial canned dog food was fed daily and free access to drinking water was allowed. The cages were cleaned and chemically disinfected each day. Preceding irradiation, the food consumption, nature of the feces, rectal temperature, and heart rate were recorded daily, and control blood determinations of hematocrit, hemoglobin, total and differential leucocyte counts were obtained. Dogs exhibiting abnormal clinical or blood pictures were excluded from the study. All food was withheld for 24 hours before irradiation.

A 1000 curie cobalt 60 irradiation facility was used as the source of ionizing radiation (13). Each dog was placed in a single compartment lucite cage, rotated on a platform at three revolutions per minute, and exposed to 600 r of total-body radiation (mid-tissue dose) from above. The source to mid-tissue distance was 54.5 cm. Prior to each series of irradiations the mid-tissue dose rate (27 to 32 r/min) was determined in a rectangular paraffin dog phantom with a 100 r Victoreen thimble chamber. The details of dosimetry and specifications of the radiation cage were described in a previous paper (14).

The doses of the chemical agents used in this study and the interval between the administration of the chemical mixture and the time of irradiation were derived from the results of preliminary experiments in dogs in which the protective capabilities of various individual and combined chemical agents were tested.
The chemical agents tested were para-aminopropiophenone (PAPP)\(^1\), S. β-aminoethylisothiuronium (AET)\(^2\), and 5-hydroxytryptamine (serotonin)\(^3\). All solutions were prepared aseptically within five minutes of their intended use. The PAPP was dissolved, with slight warming, in propylene glycol at a concentration of 10 mg/ml. The AET and serotonin were dissolved together in 3 to 5 ml of normal saline and the final mixture adjusted to a pH of 6.3 to 6.6. A one per cent solution of methylene blue was prepared in normal saline. The PAPP was administered by slow intravenous injection 25 to 30 minutes before irradiation at doses of 4 to 5 mg/kg of body weight. The mixture containing a total dose of 225 mg of AET and 32.5 mg of serotonin per dog was administered intraperitoneally 10 to 15 minutes before irradiation. Immediately following irradiation methylene blue at a dose of 2 mg/kg was administered intravenously to those dogs which had previously received PAPP.

The groups of dogs designated to receive post-irradiation supportive therapy were treated according to the following regimen:

a. Antibiotics: Antibiotics were administered only after an elevation of the rectal temperature above 102.5°F was noted. Initially 300,000 units of procaine penicillin G plus 0.5 gm of streptomycin sulfate were administered intramuscularly once daily. If no response was observed in 24 hours, the dosage was doubled. On the subsequent day, if no reduction in rectal temperature was noted, chlortetracycline or oxytetracycline (250 to 500 mg per day) were added to the treatment, given orally if tolerated, or otherwise intravenously. The antibiotic therapy was continued until death, or until an improved clinical condition and a rising leucocyte count indicated recovery.

b. Parenteral Fluids: 150 to 300 ml of 15 per cent dextrose in saline intravenously by slow drip, or 150 to 300 ml of 5 per cent dextrose in water subcutaneously were administered to the dogs once daily only when they refused all food. These parenteral fluids were supplemented with potassium chloride (10 meq/l), vitamins C and B complex, and broad spectrum antibiotics. As blood electrolyte determinations were not made in this study, identical solutions were administered to all dogs without attempting to correct the fluid and electrolyte balance of each dog individually.

---

\(^1\)Obtained from Eastman Kodak Company, Rochester, N. Y.

\(^2\)In the form of the Br·IBr\(^-\) salt, obtained from Schwarz Laboratories, Mount Vernon, N. Y.

\(^3\)In the form of the creatinine sulfate salt, obtained from the California Foundation for Biochemical Research, Los Angeles, Calif.
c. Miscellaneous Treatments: Other therapy was given as indicated by the development of clinical symptoms. A gastrointestinal adsorbent (Kaopectate, Upjohn) was given orally when diarrhea was noted, and topical antibiotics and cutaneous wound therapy were used when skin infections were present. All dogs in the treated group were given 0.5 ml/kg of body weight of hyperimmune serum (anti-canine distemper, hepatitis, and leptospirosis) subcutaneously at 14-day intervals following irradiation.

Following irradiation the food consumption, rectal temperature, and nature of the feces of both treated and untreated dogs were recorded daily. Every 3 to 5 days blood was collected for the determination of hematocrit, hemoglobin, and total and differential leukocyte count. Deaths were recorded daily. The dogs living beyond 30 days were counted as survivors and were retained for future study. All dogs which died following irradiation were necropsied.

III. RESULTS

In this study 68 dogs were exposed to 600 r of acute whole-body radiation from a cobalt 60 source. Under identical conditions of irradiation the LD₅₀/30 days was previously estimated at 260 r, and the LD₁₀₀/30 days at 325 r (14).

The data from individual dogs used in this study are presented in Table 1, summarized in Table 2, and graphically illustrated in Figure 1. Cumulative mortality is illustrated in Figures 2 and 3. The results of irradiating the different groups of dogs are as follows:

Group I: Among the 18 irradiated controls of 6 dogs receiving no post-irradiation supportive therapy all died, and only one of the 12 dogs receiving post-irradiation therapy survived; however, this survivor exhibited very severe signs of radiation injury, including its total refusal of food intake for 17 days, before its ultimate recovery. At the 12th post-irradiation day the cumulative mortalities were found to be 100 per cent for those without, and only 25 per cent for those with supportive therapy. The mean survival time of the non-survivors in this group was 10.7 days for those without and only 14.5 days for those with post-irradiation supportive therapy.

Group II: A total of 16 dogs were given PAPP intravenously prior to radiation exposure. Five of the 8 dogs receiving post-irradiation supportive therapy survived (62.5 per cent), while only 1 of 8 survived without supportive therapy (12.5 per cent). The mean survival time of
**Table 1**

**INDIVIDUAL MORTALITY DATA FOR DOGS IRRADIATED AT 600 r COBALT 60**

| Group IA. Control without pre-radiation chemical but with post-radiation therapy. | Dog No. | Sex | Body Wt. (kg) | Days Survived | Dog No. | Sex | Body Wt. (kg) | Days Survived |
|---|---|---|---|---|---|---|---|---|---|
| 10 | F | 0.1 | 12 | 75 | 514 | M | 11.0 | 9 |
| 13 | F | 0.3 | 13 | 20 | 710 | M | 10.7 | 12 |
| 172 | F | 7.2 | 4 | 70 | 776 | M | 9.6 | 17 |
| 389 | M | 0.7 | 12 | 20 | 808 | F | 9.8 | 18 |
| 391 | F | 8.3 | 12 | 20 | 710 | F | 9.8 | 18 |
| 401 | M | 10.1 | 13 | 20 | 766 | F | 9.8 | 18 |

**Group IB. Control without pre-radiation chemical and without post-radiation therapy.**

<table>
<thead>
<tr>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
</tr>
</thead>
<tbody>
<tr>
<td>170</td>
<td>F</td>
<td>6.5</td>
<td>11</td>
<td>714</td>
<td>M</td>
<td>10.0</td>
<td>12</td>
</tr>
<tr>
<td>171</td>
<td>F</td>
<td>6.6</td>
<td>9</td>
<td>708</td>
<td>M</td>
<td>10.0</td>
<td>12</td>
</tr>
<tr>
<td>302</td>
<td>M</td>
<td>6.6</td>
<td>9</td>
<td>714</td>
<td>F</td>
<td>9.0</td>
<td>11</td>
</tr>
</tbody>
</table>

**Group IIIA. PAPP 5 mg/kg I.V. with post-radiation therapy.**

<table>
<thead>
<tr>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
</tr>
</thead>
<tbody>
<tr>
<td>452</td>
<td>F</td>
<td>9.6</td>
<td>15</td>
<td>774</td>
<td>M</td>
<td>11.0</td>
<td>30+</td>
</tr>
<tr>
<td>652</td>
<td>F</td>
<td>10.2</td>
<td>15</td>
<td>774</td>
<td>M</td>
<td>11.0</td>
<td>30+</td>
</tr>
<tr>
<td>557</td>
<td>M</td>
<td>8.6</td>
<td>30e</td>
<td>766</td>
<td>F</td>
<td>10.2</td>
<td>30+</td>
</tr>
<tr>
<td>717</td>
<td>F</td>
<td>7.5</td>
<td>30e</td>
<td>766</td>
<td>M</td>
<td>9.6</td>
<td>30+</td>
</tr>
</tbody>
</table>

**Group IIIB. PAPP 4 mg/kg (+) or 5 mg/kg I.V. and 225 mg ACT plus 30 mg serotonin I.P. with post-radiation therapy.**

<table>
<thead>
<tr>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
</tr>
</thead>
<tbody>
<tr>
<td>545</td>
<td>F</td>
<td>4.9</td>
<td>11</td>
<td>687*</td>
<td>F</td>
<td>10.6</td>
<td>30+</td>
</tr>
<tr>
<td>546</td>
<td>M</td>
<td>11.0</td>
<td>30e</td>
<td>720</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>596</td>
<td>M</td>
<td>10.6</td>
<td>30e</td>
<td>720</td>
<td>F</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>615</td>
<td>F</td>
<td>6.6</td>
<td>30e</td>
<td>720</td>
<td>F</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>616</td>
<td>F</td>
<td>9.7</td>
<td>30e</td>
<td>775*</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>651</td>
<td>M</td>
<td>9.4</td>
<td>30e</td>
<td>710</td>
<td>F</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>652</td>
<td>F</td>
<td>10.9</td>
<td>30e</td>
<td>775*</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>654</td>
<td>F</td>
<td>11.0</td>
<td>30e</td>
<td>775*</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>655</td>
<td>M</td>
<td>9.4</td>
<td>30e</td>
<td>775*</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
</tbody>
</table>

**Group IIIB. PAPP 4 mg/kg (+) or 5 mg/kg I.V. and 225 mg ACT plus 32.5 mg serotonin I.P. without post-radiation therapy.**

<table>
<thead>
<tr>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
<th>Dog No.</th>
<th>Sex</th>
<th>Body Wt. (kg)</th>
<th>Days Survived</th>
</tr>
</thead>
<tbody>
<tr>
<td>545</td>
<td>F</td>
<td>9.6</td>
<td>15</td>
<td>687*</td>
<td>F</td>
<td>10.6</td>
<td>30+</td>
</tr>
<tr>
<td>651</td>
<td>M</td>
<td>11.0</td>
<td>30e</td>
<td>720</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>652</td>
<td>F</td>
<td>9.7</td>
<td>30e</td>
<td>720</td>
<td>F</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>655</td>
<td>M</td>
<td>9.4</td>
<td>30e</td>
<td>775*</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>654</td>
<td>F</td>
<td>11.0</td>
<td>30e</td>
<td>775*</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
<tr>
<td>655</td>
<td>M</td>
<td>9.4</td>
<td>30e</td>
<td>775*</td>
<td>M</td>
<td>10.9</td>
<td>30+</td>
</tr>
</tbody>
</table>

**Table 2**

**SUMMARY OF DRUG PROTECTION STUDIES IN DOGS (600 r COBALT 60)**

<table>
<thead>
<tr>
<th>Pre-radiation Treatment</th>
<th>Group</th>
<th>Post-radiation Therapy</th>
<th>No. of Dogs</th>
<th>Mean Survival Time (Days)</th>
<th>Per cent Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>A</td>
<td>Yes</td>
<td>12</td>
<td>1.45</td>
<td>83</td>
</tr>
<tr>
<td>PAPP (I.V.)</td>
<td>B</td>
<td>No</td>
<td>6</td>
<td>0</td>
<td>10.7</td>
</tr>
<tr>
<td>PAPP (I.V.) and ACT + Serotonin (I.P.)</td>
<td>A</td>
<td>Yes</td>
<td>22</td>
<td>14.3</td>
<td>67.5</td>
</tr>
<tr>
<td>ACT + Serotonin (I.P.)</td>
<td>B</td>
<td>No</td>
<td>12</td>
<td>14.3</td>
<td>61.8</td>
</tr>
</tbody>
</table>

---
Fig. 1. Thirty day survival of control and chemically protected dogs following 600 r of acute whole-body radiation.
Fig. 2. Cumulative mortality of control and chemically protected dogs following 600 r and with post-irradiation supportive therapy.

Fig. 3. Cumulative mortality of control and chemically protected dogs following 600 r but without post-irradiation supportive therapy.
the non-survivors in this group was not markedly influenced by the supportive therapy. The 50 per cent added survival of those receiving supportive therapy was the result of a large reduction in the number of deaths occurring between the 12th and 15th post-irradiation days.

Group III. A total of 34 dogs were given FAPP intravenously and AET plus serotonin intraperitoneally before irradiation. Eighteen of the 22 dogs with post-irradiation supportive therapy survived (81.8 per cent) as compared to only 7 survivors among 12 dogs without post-irradiation supportive therapy (58.3 per cent). The 23.5 per cent added mortality among those receiving no supportive therapy occurred between the 12th and the 18th post-irradiation days. Again no marked difference in the mean survival time among the non-survivors in this group was noted.

The immediate side-effects following the administration of these chemical agents varied from mild to severe signs of toxic reaction characterized by cyanosis, dullness, weakness, hyperpnea, tachycardia, excessive saliva, straining, urination, and defecation. Occasionally these symptoms became severe enough to produce complete prostration. The intravenous administration of 2 mg/kg of methylene blue immediately following irradiation, however, rapidly abolished these toxic side-effects, and recovery was essentially complete within 3 to 4 hours. In spite of these toxic reactions, drug-induced mortality was not encountered in this study.

The average hematocrits and total leucocyte counts of the control and chemically treated dogs, regardless of eventual survival or non-survival, are illustrated in Figures 4 and 5. Following irradiation, a rapid fall in leucocytes, especially lymphocytes, was seen in all dogs. It appears that the irradiated controls (Group I) exhibited the greatest and most rapid drop in leucocytes, whereas the dogs receiving PAPP, AET, and serotonin (Group III) showed the least pronounced leucopenia. The leucocyte pictures of dogs receiving identical pre-irradiation treatment, with or without post-irradiation supportive therapy, were not noticeably different. The changes in the hemoglobin levels were found to be closely parallel to those of the hematocrit values and are not therefore included in the graphs. The hematocrit and hemoglobin levels decreased progressively following irradiation, but there were no apparent differences between the control and chemically protected dogs.

A comparison of the average hematocrit and leucocyte values of the survivors and the non-survivors within each group of control and chemically treated dogs is presented in Figures 6 to 11. The average leucocyte counts of the non-survivors fell well below those of the
Fig. 4. Hematocrits and total leucocyte counts of control and chemically protected dogs receiving post-irradiation supportive therapy.

Fig. 5. Hematocrits and total leucocyte counts of control and chemically protected dogs receiving no post-irradiation supportive therapy.
Fig. 6. Hematocrits and total leucocyte counts of the survivors and non-survivors in the group of control irradiated dogs receiving post-irradiation supportive therapy (Group Ia.).

Fig. 7. Hematocrits and total leucocyte counts of the non-survivors in the group of control irradiated dogs receiving no post-irradiation supportive therapy (Group Ib.).
Fig. 8. Hematocrits and total leucocyte counts of the survivors and non-survivors in the group of PAPP treated dogs receiving post-irradiation supportive therapy (Group IIa.).

Fig. 9. Hematocrits and total leucocyte counts of the survivors and non-survivors in the group of PAPP treated dogs receiving no post-irradiation supportive therapy (Group IIa.).
Fig. 10. Hematocrits and total leucocyte counts of the survivors and non-survivors in the group of dogs treated with PAPP, AET, and serotonin and receiving post-irradiation supportive therapy (Group IIIa.).

Fig. 11. Hematocrits and total leucocyte counts of the survivors and non-survivors in the group of dogs treated with PAPP, AET, and serotonin but receiving no post-irradiation supportive therapy (Group IIIb.).
survivors. The leucocyte counts of dogs which eventually survived began to rise after the second week, approaching pre-irradiation levels by 60 days. In general, the hematocrit and hemoglobin values decreased more rapidly among the non-survivors. The return of the hematocrit and the hemoglobin to pre-irradiation levels among the survivors was not always complete even after 63 days.

IV. DISCUSSION

Numerous chemical agents, including PAPP, AET, and serotonin, have been found to protect rodents from radiation induced lethality (16, 17, 21). However, such chemical agents were too toxic when administered to dogs in doses comparable on a weight basis to those used in rodents (4). On the other hand, the reduction of the dosages to less toxic levels resulted in greatly diminished or insignificant protective activity. At present, no single chemical agent has been shown to provide satisfactory radiation protection to dogs at non-toxic dose levels.

It has been demonstrated in mice that mixtures of chemical agents at a lower dosage for each offered, without additive toxicity, greater radiation protection than any one of the agents used alone (1). The successful use of mixtures of radio-protective agents in dogs has also been reported (5, 6).

The combination of chemical agents used in the present study was derived from earlier screening experiments in dogs at this laboratory. It was found that the pre-irradiation administration of PAPP (4 to 5 mg/kg) intravenously and AET (225 mg per dog) plus serotonin (32.5 mg per dog) intraperitoneally provided a high degree of protection from radiation induced lethality. The doses of these chemical agents given to dogs were about 10 to 50 times less than the doses required to produce effective radiation protection in mice (1). In spite of the development of toxic side-effects following the administration of this chemical mixture to dogs, no drug-induced mortality was encountered. Furthermore, much of the toxic effect resulted from PAPP-induced methemoglobinemia and could be reversed by methylene blue.

Little information is available concerning the exact mechanisms of the radio-protective action of PAPP, AET, and serotonin.

PAPP produces a rapidly developing, pronounced methemoglobinemia when administered intravenously to dogs (15). Its radio-protective activity has been explained on the basis of the resultant tissue hypoxia (16).
AET is among the most effective of the numerous amine and sulfhydryl compounds that have been tested for radio-protective activity in mice (17). It has been postulated that these compounds protect by virtue of their direct reaction with radiation-induced radicals, producing stable hybrids which then react preferentially with other radicals rather than with sensitive biological material. The isothiuronium group of AET is apparently responsible for its protective activity (15). In the present study, all solutions of AET were adjusted to a pH of 6.3 to 6.6 just before administration. AET transforms readily to 2-mercaptoethylguanidine (MEG) at a pH around neutral (19). It is assumed therefore that some of the observed radio-protective effect was due to MEG.

It has recently been demonstrated that serotonin probably owes its protective activity to its ability to lower tissue oxygen tension in certain critical organs such as the spleen (20). This effect is apparently due to the smooth muscle effects of serotonin, producing vasconstriction (21).

The beneficial effect of symptomatic post-irradiation supportive therapy in both control and chemically protected dogs is demonstrated in this study. By administering antibiotics, parenteral fluids, whole-blood, and vitamins to supra-lethally irradiated control dogs, increase of 4 days in the mean survival time was noted, and in one dog, survival beyond 30 days was attained. The beneficial effect among chemically protected dogs is evidenced by a large decrease in 30 day mortality.

A precise evaluation of each phase of the post-irradiation treatment program was not intended in the design of these experiments; however, the sequellae of hemorrhage, infection, and anemia occurring within the first 30 days after radiation were certainly altered by these treatments. On the basis of subjective clinical evaluation of the individual dogs in the treated and untreated groups, it is a general impression that, in untreated dogs in which the total leukocyte count fell below about 1000 per mm$^3$, overwhelming infection leading to death was the invariable consequence. However, among the dogs receiving supportive therapy, the onset of overwhelming infection was often prevented or delayed by antibiotic therapy, even in the face of total leukocyte depression far below 1000 per mm$^3$. Furthermore, even in cases where infection, hemorrhage and anemia developed to a degree producing a complete cessation of oral intake, it was occasionally possible to prolong life by the vigorous administration of electrolytes, glucose, vitamins, fluids, and whole blood until a subsequent rise in leukocyte count initiated the recovery process.
V. CONCLUSIONS

Effective protection of dogs from radiation induced lethality can be provided by the pre-irradiation administration of para-aminopropiophenone (PAPP), S₃-aminoethylisothiuronium (AET), and serotonin in combination whereas PAPP alone is relatively ineffective. This combination of chemical agents is only moderately toxic, and much of its toxic effect may be rapidly abolished by the administration of methylene blue following irradiation. Vigorous post-irradiation therapy with antibiotics, vitamins, parenteral fluids, and whole-blood markedly decreases the mortality among chemically protected dogs, and increases the survival time of protected dogs.

VI. RECOMMENDATION

It is recommended that this and other combinations of chemical agents be investigated further in dogs with a view toward possible human application.

VII. REFERENCES


7. Burnett, W. T. and D. G. Doherty. Additive effects of S,β-
aminoethylisothiuronium Br-HBr, bone marrow, and strepto-

antibiotics of dogs exposed to total-body X-irradiation. USAEC

on the radiation syndrome in dogs. Am. J. Path. 28: 25-36,
1952.

10. Furth, F. W., M. P. Coulter, R. W. Miller, J. W. Howland,
and S. J. Swisher. The treatment of the acute radiation syn-
drome in dogs with aureomycin and whole blood. J. Lab.

of terramycin on the acute radiation syndrome in dogs. Fed.

DeBottis, and A. Konnerth. The use of vitamin fortified
antibiotics in the therapy of the acute radiation syndrome in

high level cobalt 60 irradiation facility for radiobiological

conditions for acute whole-body irradiation of dogs with
cobalt 60. USAMRL Report No. 483, Ft Knox, Ky., 1961.

Methemoglobinemia after administration of p-aminoaceto-
phenone and p-aminopropiophenone. J. Pharmacol. and
Exper. Therap. 80: 31 38, 1944.

aminopropiophenone against lethal doses of X-radiation.


DISTRIBUTION LIST OF USAMRL REPORTS

Project No. 6X44-14-001 Biological and Medical Aspects of Ionizing Radiation

AGENCY - DEFENSE

No. of Copies

10 Armed Services Technical Information Agency, Arlington Hall Sta., Arlington Hall, Virginia

AGENCY - US ARMY

6 Army Attache, Box 79, Navy 100 Fleet Post Office, New York, New York. Attn: John C. Jones, Jr., Colonel, Army Attache (Medicine)

6 Army Institute of Pathology, 6825 16th Street N.W., Washington 25, D.C.

1 Brooke Army Medical Center, US Army Surgical Research Unit, Library, Building 2663, Fort Sam Houston, Texas

1 Brooke Army Medical Center, Army Medical Service School, Fort Sam Houston, Texas

1 Brooke General Hospital, Medical Library, Box 151, Fort Sam Houston, Texas

5 Brooke General Hospital, Radiotopes Clinic, Brooke Army Medical Center, Fort Sam Houston, Texas

1 Brooke General Hospital, Radiotopes Section, Brooke Army Medical Center, Fort Sam Houston, Texas

1 Chief of Chemical Corps, Department of the Army, Washington 25, D.C., Attn: DC-160/ARC

1 Chief of Engineers, Department of the Army, Washington 25, D.C., Attn: ENG

1 Chief of Ordnance, CENCTB, Washington 25, D.C., Attn: Proc & Spec, Projects Section

1 Chief Research and Development, Army Research Office, Department of the Army, Washington 25, D.C., Attn: F. C. Quinby, Chief of Life Sciences Division

1 Chief Research and Development, Department of the Army, Room 3D-643, Washington 25, D.C., Attn: Lt Colonel James B. Montgometry, Life Sciences Division, Army Research Office

1 Chief Research and Development, Department of the Army, Research Office, Washington 25, D.C., Attn: Scientific Information Branch

1 Fitzsimons General Hospital, US Army Medical Research and Nutrition Laboratory, Denver 30, Colorado

1 Fitzsimons General Hospital, Medical Technical Library, Denver 30, Colorado

1 Letterman General Hospital, Medical Library, San Francisco, California

1 Madison General Hospital, Medical Library, Madison, Wisconsin

1 Quartermaster Food and Container Institute, Library Branch, 1819 W. Pershing Road, Chicago 9, Illinois

1 Quartermaster Research and Engineering, Field Evaluation Agency, Fort Lee, Virginia, Attn: Technical Library

1 Quartermaster Board, US Army, Fort Lee, Virginia, Attn: President

1 Quartermaster Research and Engineering Center, Watich, Massachusetts, Attn: Technical Library

1 Resolute Arsenal, Resolute Arsenal, Alabama, Attn: CENCTB-NR


2 US Army Chemical Warfare Laboratories, Directorate of Medical Research, Army Chemical Center, Maryland

1 US Army Chemical Corps Research and Development Command, US Army Biological Warfare Laboratories, Fort Detrick, Maryland, Attn: Technical Library Branch, Records Room

1 US Army Command and General Staff College, Fort Leavenworth Kansas, Attn: Archives

1 US Army Dispensary, Fort Sam Houston, Springfield Army, Springfield, Massachusetts

1 US Army Engineer Research and Development Laboratory, Fort Belvoir, Virginia, Attn: Technical Documents Center

1 US Army Environmental Health Laboratory, Army Chemical Center, Maryland

10 US Army, Europe, Medical Division, APO 448, New York, New York

1 US Army, Medical Command, Japan, APO 343, San Francisco, California

2 US Army Medical Logistics Branch, Office of the Chief Surgeon, Box 503, Balton Heights, Guam Zone
US ARMY - CONTINUED

3 US Army Medical Research and Development Command, Commanding General, Main Navy Building, Washington 25, D. C.
1 US Army Medical Research Unit, Institute of Medical Research, Kuala Lumpur, Malaya
1 US Army Ordinance Arsenal Frankford, Philadelphia 37, Pennsylvania, Attn: Human Factors Section, 1734
1 US Army Ordinance Arsenal, Frankford, Philadelphia 37, Pennsylvania, Attn: A. Charles Karr, Chief Human Factors Section, ONR-1734
2 US Army Ordinance Tank Automotive Command, Detroit Arsenal, Center Line, Michigan, Attn: OOM-REO
1 US Army, Pacific, APO 958, San Francisco, California, Attn: Surgeon
1 US Army Signal Research and Development Laboratory, Fort Monmouth, New Jersey, Attn: SGRAM-E
1 US Army Standardization Group, Canada, Office of the Senior Standardization Representative, Directorate of Equipment Policy, Canadian Army Headquarters, Ottawa, Canada, Attn: Colonel Joseph R. Blair, MC, Medical Liaison Officer
2 US Army Transportation Research and Engineering Command, Fort Eustis, Virginia, Attn: Chief, Technical Information Division
2 US Army Tropical Research Medical Laboratory, APO 651, New York, New York
1 US Army War College, Carlisle Barracks, Pennsylvania, Attn: Library
1 US Continental Army Command, Medical Section, Fort Monroe, Virginia
5 US Atomic Energy Commission, Technical Information Service Extension, P. O. Box 62, Oak Ridge, Tennessee
1 Valley Forge General Hospital, Phoenixville, Pennsylvania, Attn: Medical Library
1 Walter Reed Army Institute of Research, Division of Neuropsychiatry, Washington 12, D. C.
1 Walter Reed Army Institute of Research, Department of Atomic Casualties Studies, Walter Reed Army Medical Center, Washington 12, D. C.
5 Walter Reed Army Institute of Research, Office of the Director, Walter Reed Army Medical Center, Washington 12, D. C.
1 Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington 12, D. C., Attn: Paul S. Marshall, Adjunct
1 Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington 12, D. C., Attn: Stanley W. Wettner, M. D.
2 Walter Reed General Hospital, Audiology and Speech Center, Walter Reed Army Medical Center, Washington 12, D. C., Attn: James P. Albright, Major, MC
1 Walter Reed Army Medical Center, US Army Medical Service, Historical Unit, Washington 12, D. C., Attn: Lucy W. Immore, Chief, General Reference and Research Branch
1 Watervliet Arsenal OUEB-R, Technical Library, Watervliet, New York

AGENCY - US NAVY

1 Bureau of Aeronautics (AE-14) Department of the Navy, Washington 25, D. C.
2 Bureau of Medicine and Surgery, Research Division (711) Department of the Navy, Washington 25, D. C.
1 Bureau of Naval Operations (OPNAV) Operations Evaluation Group, Navy Department, Washington 25, D. C.
1 Bureau of Naval Weapons, (NAVWEAP) Navy Department, Washington 25, D. C.
2 Bureau of Naval Weapons, Department of the Navy, Washington 25, D. C., Attn: Code MMO, Pyrotechnics Branch
2 Bureau of Ships, Physics and Oceanography Branch, Main Navy Building, 16th and Constitution Avenue, Washington 25, D. C.
1 Bureau of Yards and Docks, Department of the Navy, Washington 25, D. C., Attn: Code D-44G
1 Marine Corps Educational Center, Archives and Historical Group, Marine Corps School, Quantico, Virginia
1 Naval Air Crew Equipment Laboratory, Naval Air Material Center, Philadelphia 12, Pennsylvania
1 Naval Air Engineering Facility, Naval Air Material Center, Philadelphia 12, Pennsylvania, Attn: Technical Library
1 Naval Medical Field Research Laboratory, Camp Lejeune, North Carolina, Attn: Library
No. of
Copies

US NAVY - CONTINUED

1 Naval Medical Research Institute, Technical Reference Library, National Naval Medical Center, Bethesda 14, Maryland
1 Naval Research (Code 486) Special Assistant for Medical and Allied Sciences, Department of the Navy, Washington 25, D. C.
10 Naval Research Branch Office, Navy 100, Box 38. Fleet Post Office, New York, New York
1 US Naval Air Development Center, Aviation Medical Acceleration Laboratory, Johnsville, Pennsylvania. Attn: Library
2 US Naval Air Station, Chief of Naval Air Technical Training, Memphis 3, Tennessee. Attn: Staff Medical Officer
1 US Naval Civil Engineering Laboratory, Commanding Officer and Director (Code 121) Port Hueneme, California
2 US Naval Medical School, National Naval Medical Center, Bethesda 14, Maryland
2 US Naval Missile Center, Point Mugu, California. Attn: Librarian Code 2121
1 US Naval Radiological Defense Laboratory, San Francisco 24, California. Attn: Director (222)
1 US Naval Ordnance Test Station, Medical Officer, Station Hospital, Code 68, China Lake, California
1 US Naval School of Aviation Medicine, US Naval Aviation Medical Center, Director of Research, Pensacola, Florida
1 US Naval School of Aviation Medicine, US Naval Aviation Medical Center 54, Pensacola, Florida. Attn: Commanding Officer
2 US Naval School of Aviation Medicine, US Naval Aviation Medical Center, Pensacola, Florida. Attn: Assistant Director of Research
1 US Naval Supply and Research and Development, Facility Technical Library, 29th Street and Third Avenue, Brooklyn 32, New York
1 US Naval Weapons Plant, Experimental Diving Unit, Washington 25, D. C.

AGENCY - AIR FORCE


AIR RESEARCH AND DEVELOPMENT COMMAND

2 Wright Air Development Center, Wright-Patterson Air Force Base, Ohio. Attn: (WELDC)
1 Wright Air Development Center, (WELMT-Library). Wright-Patterson Air Force Base, Ohio
1 Air Proving Ground Center, Air Research and Development Command. (OGTC) US Air Force, Eglin Air Force Base, Florida
2 Air Training Command. (ATCC) Randolph Air Force Base, Texas
1 Arctic Aeromedical Laboratory, APO 731, Sent Jc. Washington. Attn: Librarian
1 Assistant for Ground Safety, DLAB, US Air Force, Washington 25, D. C.
1 Langley Research Center, National Aeronautics and Space Administration, Langley Field, Virginia. Attn: Mrs. Elizabeth R. Gunin, Librarian
7 US Air Force Aerospace Medical Center (ATC) School of Aviation Medicine (SAM-41.3) Brooks Air Force Base, Texas
1 US Air Force, Aerospace Medical Center (ATC) US Air Force Hospital, Lackland Air Force Base, Texas. Attn: Medical Library
1 US Air Force, Strategic Air Command, Office of the Surgeon, Offutt Air Force Base, Nebraska

GOVERNMENTAL AGENCIES

1 Argonne National Laboratory, P. O. Box 399, Lemont, Illinois. Attn: Maylunda D. Young
GOVERNMENTAL AGENCIES - CONTINUED

1 Civil Aeromedical Research Center, Aeronautical Center, P. O. Box 1082, Oklahoma City, Oklahoma.

1 Civil and Defense Mobilization, Technical Library, Room G-3-B, Battle Creek, Michigan.


1 National Institutes of Health, Library, Bethesda 14, Maryland.

1 National Institutes of Health, National Cancer Institute, Radiation Branch, Bethesda 14, Maryland.

1 National Institutes of Health, Division of Research Grants, Bethesda 14, Maryland.

1 National Institutes of Health, National Institutes of Health, National Cancer Institute, Radioisotopes Branch, Bethesda 14, Maryland.

1 National Institutes of Health, Library, 7th and Independence Avenue, S. W., Washington 25, D. C.

2 National Research Council, Division of Medical Sciences, Medical Records, 2101 Constitution Avenue, Washington 25, D. C.


1 US Atomic Energy Commission, Division of Biology and Medicine, Washington 25, D. C., Attn: Mr. Robert L. Crooble, Director, ETO.

OTHER AGENCIES

1 Arctic Health Research Center, Library, P. O. Box 540, Anchorage, Alaska.

1 Boeing Airplane Company, Central Medical Library, 11-40, P. O. Box 3707, Seattle 24, Washington.

1 Boeing Airplane Company, Wichita Division, Library, Wichita 1, Kansas.

2 Department of Health, Education and Welfare, Division of Radiological Health - KEK, Room S630, East Eck Building, Washington 25, D. C., Attn: Information Officer.


1 Electric Boat, Division of General Dynamics Corporation, Special Projects Division, Groton, Connecticut, Attn: Mr. William J. King, Human Factors Section.

1 General Electric Company, Technical Military Planning Office, 735 State Street, Santa Barbara, California.

1 The John Cramer Library, 88 East Randolph Street, Chicago 1, Illinois.

1 Kings County Hospital, Department of Anesthesiology, Brooklyn, New York, Attn: Dr. Stanley W. Waltman.

1 Lebanon Hospital, Lancaster and City Line Avenues, Philadelphia 31, Pennsylvania, Attn: Dr. Steven H. Haas, Division of Research.

1 Lasfield Research Institute, McMinnville, Oregon.

1 Mayo Clinic, Section of Biophysics, Rochester, Minnesota, Attn: Dr. Kenneth N. Cule.

1 Moore Johnson and Company, Medical Department, 2401 W. Pennsylvania Street, Evansville 21, Indiana.

1 National Aeronautics and Space Administration, 1300 I Street, N. W., Washington 25, D. C., Attn: Mr. Bertram A. Maloney, Director of Technical Information.

1 Sensory Biophysics Group, Pattern Recognition Department, IBM Research Center, Box 218, Yorktown Hts., New York.

1 Space Technology Laboratories, Inc., Information Services, P. O. Box 58001, Document Acquisition Group, Los Angeles 45, California.

1 The Rand Corporation, 1700 Main Street, Santa Monica, California, Attn: Library.

1 Yerkes Laboratories of Primate Biology, Orange Park, Florida.

MEDICAL COLLEGE/SCHOOL LIBRARIES AND DEPARTMENTS

1 Albany Medical College Library, New Scotland Avenue, Albany 5, New York.

1 Bowman Gray School of Medicine, Winston-Salem, North Carolina, Attn: Library.

1 College of Medical Evangelists, White Memorial Medical Library, 1720 Brooklyn Avenue, Los Angeles 24, California.

1 College of Medical Evangelists, Vernier Radcliffe Memorial Library, Lone Linda, California.
<table>
<thead>
<tr>
<th>No. of Copies</th>
<th>MEDICAL COLLEGE/SCHOOL, LIBRARIES AND DEPARTMENTS CONTINUED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Columbia University, Medical Library, 630 West 168th Street, New York 32, New York</td>
</tr>
<tr>
<td>1</td>
<td>Cornell University, Medical College Library, 1300 York Avenue, New York 21, New York</td>
</tr>
<tr>
<td>1</td>
<td>Creighton Medical Library, 302 North 14th Street, Omaha 2, Nebraska</td>
</tr>
<tr>
<td>1</td>
<td>Dartmouth College Medical Library, Baker, Hanover, New Hampshire</td>
</tr>
<tr>
<td>1</td>
<td>Florida State University, Department of Psychology, Tallahassee, Florida. Attn: W. W. Dawson</td>
</tr>
<tr>
<td>2</td>
<td>George Washington University, Hissong Resources Research Office, P. O. Box 3596, Washington 7, D. C. Attn: Library</td>
</tr>
<tr>
<td>1</td>
<td>Harvard Medical Library, 25 Shattuck Street, Boston 15, Massachusetts</td>
</tr>
<tr>
<td>1</td>
<td>Indiana University Medical Center, School of Medicine Library, 1100 West Michigan Street, Indianapolis 7, Indiana</td>
</tr>
<tr>
<td>1</td>
<td>Jefferson Medical College Library, 1325 Walnut Street, Philadelphia 7, Pennsylvania</td>
</tr>
<tr>
<td>1</td>
<td>Johns Hopkins University, Operations Research Office, 6315 Arlington Road, Bethesda, Maryland, Washington 14, D. C. Attn: Library</td>
</tr>
<tr>
<td>1</td>
<td>Johns Hopkins University, Welch Medical Library, 1900 East Monument Street, Baltimore 5, Maryland</td>
</tr>
<tr>
<td>1</td>
<td>Marquette University, Dental-Medical School, 500 North 15th Street, Milwaukee 3, Wisconsin</td>
</tr>
<tr>
<td>1</td>
<td>Medical College of Virginia, Tompkins-McCaw Library, Richmond 19, Virginia</td>
</tr>
<tr>
<td>1</td>
<td>New York Academy of Medicine, 2 East 103rd Street, New York 29, New York. Attn: Library</td>
</tr>
<tr>
<td>1</td>
<td>New York University, Bellevue Medical Center Library, 550 First Avenue, New York 16, New York</td>
</tr>
<tr>
<td>1</td>
<td>Northwestern University Medical School, Archibald Church Library, 300 East Chicago Avenue, Chicago 11, Illinois</td>
</tr>
<tr>
<td>1</td>
<td>Ohio State University, Chemical Abstracts, Columbus 10, Ohio. Attn: Library</td>
</tr>
<tr>
<td>1</td>
<td>Ohio State University, Operations Research Group, Engineering Experiment Station, 156 West Tenth Avenue, Columbus 10, Ohio</td>
</tr>
<tr>
<td>1</td>
<td>Ohio State University, School of Optometry, Topaz Library of Visual Science, 336 West Tenth Avenue, Columbus 10, Ohio</td>
</tr>
<tr>
<td>1</td>
<td>Ohio State University, Topaz Library, School of Optometry, 336 West Tenth Avenue, Columbus 10, Ohio</td>
</tr>
<tr>
<td>1</td>
<td>Rush Medical College Library, 1758 West Harrison Street, Chicago 12, Illinois. Attn: Frida Pflieke, Librarian</td>
</tr>
<tr>
<td>1</td>
<td>St. Louis University, School of Medicine, 1402 South Grand Avenue, St. Louis 4, Missouri. Attn: Library</td>
</tr>
<tr>
<td>1</td>
<td>Stanford University, Department of Physiology, Stanford, California. Attn: Dr. J. M. Crisman</td>
</tr>
<tr>
<td>1</td>
<td>Stanford University Medical Center, 300 Pasteur Drive, Stanford, California. Attn: Lane Medical Library</td>
</tr>
<tr>
<td>1</td>
<td>State University of Iowa, College of Medicine Library, Medical Laboratories Building, Iowa City, Iowa</td>
</tr>
<tr>
<td>1</td>
<td>State University of New York, Downstate Medical Center, Department of Anesthesiology, 450 Clarkson Avenue, Brooklyn, New York. Attn: Dr. Stanley W. Neitman</td>
</tr>
<tr>
<td>1</td>
<td>State University of New York, Downstate Medical Center, Medical Library, 450 Clarkson Avenue, Brooklyn 3, New York</td>
</tr>
<tr>
<td>1</td>
<td>Texas Medical Center Library, Jesse H. Jones Library Building, Texas Medical Center, Houston 25, Texas</td>
</tr>
<tr>
<td>1</td>
<td>Tufts University, Institute for Applied Experimental Psychology, Medford 55, Massachusetts. Attn: Paul G. Ronca</td>
</tr>
<tr>
<td>1</td>
<td>Vanderbilt University School of Medicine, Department of Medicine, Nashville 5, Tennessee. Attn: George R. Moses, M.D. Assoc. Prof. of Medicine, Director Radiosotope Center</td>
</tr>
<tr>
<td>1</td>
<td>University of Alabama, Medical Center Library, 1223 Seventeenth Avenue South, Birmingham 3, Alabama</td>
</tr>
<tr>
<td>1</td>
<td>University of Arkansas, Medical Center Library, 4001 West Markham, Little Rock, Arkansas</td>
</tr>
</tbody>
</table>
University of Colorado. An ashamed Medical Research Library, 8010 E. 10th Street, Denver 26, Colorado
1 University of Colorado, Civil Defense Research Project, 1301 South 46th Street, Richmond, California
1 University of Chicago, U.S. National Medical Research Unit No. 1, Berkeley 4, California
1 University of California Medical Center, Biomedical Library, Los Angeles 24, California
1 University of California, Civil Defense Research Project, 1301 South 46th Street, Richmond, California
1 University of Chicago, US Air Force Radiation Laboratory, 5700 E. 58th Street, Chicago 37, Illinois, Attn: Dr. Kenneth P. Dubois
1 University of Chicago, Faculty Exchange Box 184, Chicago 37, Illinois, Attn: W. D. Neff, Laboratory of Physiological Psychology
1 University of Cincinnati, Lettering Laboratory, Eden and Bethesda Avenue, Cincinnati 19, Ohio
1 University of Illinois, Department of Psychology, Urbana, Illinois, Attn: Dr. V. E. Rapaport
1 University of Illinois, Aeronautical Laboratory, 840 South Wood Street, Chicago 12, Illinois, Attn: Dr. John F. Maburger
1 University of Kansas Medical Center,チェックニング Medical Library, Kansas City 12, Kansas
1 University of Louisville, School of Medicine, Louisville Medical Library, 101 West Chestnut Street, Louisville 2, Kentucky
1 University of Maryland, Health Sciences Library, 111 South Greene Street, Baltimore 1, Maryland
1 University of Miami, School of Medicine, Jackson Memorial Library, 1000 N. W. 17th Street, Miami 33, Florida
1 University of Michigan, Serials and Documents Section, General Library, Ann Arbor, Michigan
1 University of Minnesota Medical Library, Gift and Exchange Department, Minneapolis 14, Minnesota
1 University of Mississippi, Medical School, Rowland Medical Library, Jackson, Mississippi
1 University of Missouri, Medical Library, Columbia, Missouri
1 University of Nebraska, College of Medicine Library, 2nd and Dewey Avenue, Omaha 3, Nebraska
1 University of North Carolina, Division of Health Affairs Library, North Carolina Memorial Hospital, Chapel Hill, North Carolina
1 University of Oklahoma Medical Center, 501 N. E. 13th Street, Oklahoma City, Oklahoma, Attn: Library
1 University of Oregon Medical School Library, 3191 S. W. Son Jackson Park Road, Portland 1, Oregon
1 University of Pittsburgh, Falk Library of the Health Sciences, Pittsburgh 22, Pennsylvania
1 University of Rochester, Atomic Energy Project, Technical Report Control Unit, P. O. Box 297, Station J, Rochester 28, New York
1 University of Southern California, School of Medicine Library, University Park, Los Angeles 7, California
1 University of South Dakota, Medical Library, Vermillion, South Dakota, Attn: Medical Library
1 University of Tennessee, Department of Bacteriology, Knoxville, Tennessee, Attn: Dr. D. Frank Holtman
1 University of Tennessee, Institute of Clinical Investigation, Clinical Physiological Laboratories, Memphis 3, Tennessee, Attn: Dr. Gerald B. Sarr
1 University of Tennessee, Moody Memorial Library, 22 S. Dudley, Memphis 3, Tennessee
1 University of Texas, The Radiobiological Laboratory, ADIC Box 189, Austin, Texas
1 University of Texas, Medical Branch Library, Galveston, Texas
1 University of Utah, Medical Library, Salt Lake City 12, Utah
1 University of Vermont, College of Medicine Library, Burlington, Vermont
1 University of Virginia Hospital, Medical Library, Charlottesville, Virginia
1 University of Washington, Health Sciences Library, Seattle 5, Washington
No. of MEDICAL COLLEGE/SCHOOL LIBRARIES AND DEPARTMENTS - CONTINUED

Copies
1 University of Wisconsin Medical Library, S. W. I. Building, W. Charter Street, Madison, Wiscon
2 University of West Virginia, Medical Center Library, Morgantown, West Virginia

FOREIGN
6 British Army and Navy Medical Liaison Officer, B. J. S. M. (Army Staff) 1800 K. Street, N. W., Washington 25, D. C.
7 Canadian Liaison Officer, Office of the Surgeon General, US Army, Room 2709, Main Navy Building, Canadian Joint Staff, (Washington) Washington 25, D. C.
8 Defence Research Member, Canadian Joint Staff, (Washington) Room 2709, Main Navy Building, Washington 25, D. C.
9 Laboratoire de Pathologie et Therapeutique Generales, 32 Boulevard de la Constitution, Liège, Belgique, Attn: Directeur Professeur L. M. Bacc
10 Physics Research Laboratories, Upper Redlands Road, Reading, Berkshire, England, Attn: Prof. R. W. Ditchburn
11 Royal Society of Medicine Library, 1 Wimpole Street, London W. 1, England
AD
Accession No.
US Army Medical Research Lab, Ft. Knox, Ky.
REDUCTION OF RADIATION LETHALITY IN DOGS BY
CHEMICAL MIXTURE - R. I. H. Beng and D. E.
Davidson, Jr., w/tech assist of R. M. Dunton
V. L. Orten, and H. S. Kiesgen
Report No. 208, 15 Aug 64, 15 pg 11 l h.
2 tables - Project No. X664-14-001, Unclassified Report
When 5 mg/kg of para-aminodipropophosphate (PADP) was given intravenously to
dogs 30 min. before total-body exposure to 600 r of cobalt 60 radiation
(2.0 x 10^13 r). 15% were protected from radiation death. The combined ad-
ministration of 5 mg/kg of PADP intravenously 30 min. before, and 25 mg of
5,5-diaminodipropophosphate (5-DP) intravenously 10 to 15 min. before, exposure to 600 r protected 95%. The greatest
defence (92%) was observed among dogs receiving PADP, 5-DP, and endorphins
before irradiation, and supportive therapy with hemoglobin, whole blood,
fluids and vitamins after irradiation. No deaths were attributed to the
toxic effects of the chemical agents.

AD
Accession No.
US Army Medical Research Lab, Ft. Knox, Ky.
REDUCTION OF RADIATION LETHALITY IN DOGS BY
CHEMICAL MIXTURE - R. I. H. Beng and D. E.
Davidson, Jr., w/tech assist of R. M. Dunton
V. L. Orten, and H. S. Kiesgen
Report No. 208, 15 Aug 64, 15 pg 11 l h.
2 tables - Project No. X664-14-001, Unclassified Report
When 5 mg/kg of para-aminodipropophosphate (PADP) was given intravenously to
dogs 30 min. before total-body exposure to 600 r of cobalt 60 radiation
(2.0 x 10^13 r). 15% were protected from radiation death. The combined ad-
ministration of 5 mg/kg of PADP intravenously 30 min. before, and 25 mg of
5,5-diaminodipropophosphate (5-DP) intravenously 10 to 15 min. before, exposure to 600 r protected 95%. The greatest
defence (92%) was observed among dogs receiving PADP, 5-DP, and endorphins
before irradiation, and supportive therapy with hemoglobin, whole blood,
fluids and vitamins after irradiation. No deaths were attributed to the
toxic effects of the chemical agents.